To the Editor Drs Basu and Maciejewski1 discussed time horizons in economic models, which should be long enough to capture all potential differences in outcomes associated with the treatments compared. For therapies extending survival over the entire life span, a lifetime horizon is recommended. However, survival trajectories among patient subgroups may vary and can influence survival in a nonlinear fashion. In these situations, using average survival gains to estimate a time horizon can be misleading and may result in the use of a time horizon that is shorter than the expected survival in certain subgroups.2 We illustrate the importance of 2 types of heterogeneity: heterogeneity observed at baseline (eg, age) and not observed at baseline (eg, response to treatment). The implications of the time horizon from a payer perspective are also discussed.
Majer IM, Kumar SK, Palmer S. Time Horizons in Cost Analyses. JAMA. 2019;322(6):582–583. doi:https://doi.org/10.1001/jama.2019.7853
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: